Transitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review
This review highlights cases where oral selexipag may be a suitable option when clinicians and patients participate in shared decision-making considering safety and risks/benefits. Transitions should be individualized based on clinical assessment, with appropriate monitoring and follow-up.
Authors
- Daisy Bridge
- Chad E. Miller
- Sheryl Wu (ORCID: https://orcid.org/0000-0001-8314-4787)
- J Elwing
- G. Doad
- Mrinalini Krishnan
- Charlotte Oswald
- K. Parikh
- Luis Val Maranes
- Therese Sargent
- Christina K. Benninger
- Peter O’Donovan
- Wendy Hill
Institutions
- Johnson & Johnson (United States) (US)
- Georgetown University (US)
- Banner Health (US)
- University of California System (US)
- University of California San Diego (US)
- Adelphi Group (United Kingdom) (GB)
- Banner - University Medical Center Phoenix (US)
- WakeMed (US)
- Piedmont HealthCare (US)
- MedStar Heart & Vascular Institute (US)
- University of Cincinnati (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1007/s12325-026-03491-w
- Citations
- 1
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 36.44